TWO YEAR OUTCOMES OF “TREAT AND EXTEND” INTRAVITREAL THERAPY USING AFLIBERCEPT PREFERENTIALLY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION-Reference-Cited by-同舟云学术

TWO YEAR OUTCOMES OF “TREAT AND EXTEND” INTRAVITREAL THERAPY USING AFLIBERCEPT PREFERENTIALLY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION

Published:2018-01 Issue:1 Volume:38 Page:20-28
ISSN:0275-004X
Container-title:Retina
language:en
Short-container-title:

Author:

Barthelmes Daniel,Nguyen Vuong,Daien Vincent,Campain Anna,Walton Richard,Guymer Robyn,Morlet Nigel,Hunyor Alex P.,Essex Rohan W.,Arnold Jennifer J.,Gillies Mark C.,

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Ophthalmology,General Medicine

Reference23 articles.

1. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration;Heier;Ophthalmology,2012

2. Ranibizumab and bevacizumab for neovascular age-related macular degeneration;Martin;N Engl J Med,2011

3. Ranibizumab for neovascular age-related macular degeneration;Rosenfeld;N Engl J Med,2006

4. Ranibizumab versus verteporfin for neovascular age-related macular degeneration;Brown;N Engl J Med,2006

5. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial;Chakravarthy;Lancet,2013

Cited by 79 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treat-and-Extend Versus Pro re nata Regimens of Ranibizumab and Aflibercept in Neovascular Age-Related Macular Degeneration: A Comparative Study from Routine Clinical Practice;Ophthalmology and Therapy;2024-07-08

2. European Unmet Needs in the Management of Neovascular Age-Related Macular Degeneration in Daily Practice;Ophthalmology Retina;2024-06

3. Baseline characteristics associated with the incidence of intraocular inflammation after the intravitreous injection of brolucizumab;International Ophthalmology;2023-12-03

4. Two-Year Real-World Results for Aflibercept Using the Treat-and-Extend Regimen in Neovascular Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy;Ophthalmology and Therapy;2023-11-23

5. Ten-year real-world outcomes of antivascular endothelial growth factor therapy in neovascular age-related macular degeneration using pro re nata regimen;BMJ Open Ophthalmology;2023-08